{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:48:52Z","timestamp":1785163732624,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2000,6,1]],"date-time":"2000-06-01T00:00:00Z","timestamp":959817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2000,6]]},"DOI":"10.1006\/gyno.2000.5793","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T18:50:18Z","timestamp":1032288618000},"page":"433-438","source":"Crossref","is-referenced-by-count":22,"title":["Phase II Trial of Combination Intraperitoneal Cisplatin and 5-Fluorouracil in Previously Treated Patients with Advanced Ovarian Cancer: Long-Term Follow-up"],"prefix":"10.1006","volume":"77","author":[{"suffix":"Jr.","given":"Robert J.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Braly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucille","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Somlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Longmate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Raschko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Kogut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letitia","family":"Najera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1006\/gyno.2000.5793_RF1","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1056\/NEJM199311183292108","article-title":"Cancer of the ovary","volume":"329","author":"Cannistra","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2000.5793_RF2","series-title":"Important Advances in Oncology","first-page":"121","article-title":"The importance of dose intensity in the outcome of chemotherapy","author":"Hryniuk","year":"1988"},{"key":"10.1006\/gyno.2000.5793_RF3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0002-9343(80)90472-6","article-title":"Dose: A critical factor in cancer chemotherapy","volume":"69","author":"Frei","year":"1980","journal-title":"Am J Med"},{"key":"10.1006\/gyno.2000.5793_RF4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0889-8588(18)30608-7","article-title":"Chemotherapy in ovarian carcinoma: Intravenous or intraperitoneal","volume":"2","author":"Markman","year":"1988","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1006\/gyno.2000.5793_RF5","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1200\/JCO.1988.6.11.1679","article-title":"Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma","volume":"6","author":"Piver","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5793_RF6","first-page":"23","article-title":"The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies","volume":"3","author":"Speyer","year":"1985","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.2000.5793_RF7","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2000.5793_RF8","first-page":"361a","article-title":"Randomized phase 3 study of intravenous cisplatin (cis)\/paclitaxel (pac) versus moderately high dose iv carboplatin followed by iv pac and intraperitoneal cis in optimal residual ovarian cancer: An intergroup trial (GOG, SWOG, ECOG)","volume":"17","author":"Markman","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2000.5793_RF9","first-page":"248","article-title":"Intraperitoneal chemotherapy","volume":"18","author":"Markman","year":"1991","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.2000.5793_RF10","first-page":"75","article-title":"Intraperitoneal chemotherapy in the management of ovarian cancer","volume":"12","author":"Ozols","year":"1985","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.2000.5793_RF11","first-page":"1426","article-title":"Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection","volume":"43","author":"Howell","year":"1983","journal-title":"Cancer Res"},{"key":"10.1006\/gyno.2000.5793_RF12","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1200\/JCO.1990.8.12.2054","article-title":"Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer","volume":"8","author":"Schilsky","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5793_RF13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Statist Assoc"},{"key":"10.1006\/gyno.2000.5793_RF14","first-page":"S2-1","article-title":"Chemotherapy of advanced ovarian cancer: current status and future directions","volume":"24","author":"Ozols","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.2000.5793_RF15","first-page":"293","article-title":"NCCN ovarian cancer practice guidelines. The National Comprehensive Cancer Network","volume":"10","author":"Morgan","year":"1996","journal-title":"Oncology (Huntingt)"},{"key":"10.1006\/gyno.2000.5793_RF16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.1987.5.5.756","article-title":"Dose intensity analysis of chemotherapy regimens in ovarian carcinoma","volume":"5","author":"Levin","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5793_RF17","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/cncr.2820710423","article-title":"Intraperitoneal chemotherapy in the management of ovarian cancer","volume":"71","author":"Markman","year":"1993","journal-title":"Cancer"},{"key":"10.1006\/gyno.2000.5793_RF18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/gyno.1995.1025","article-title":"Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: A Phase II Gynecologic Oncology Group trial","volume":"56","author":"Braly","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5793_RF19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/07357909709039727","article-title":"The role of chemotherapy in the management of coelomic epithelial carcinoma of the ovary","volume":"15","author":"Thigpen","year":"1997","journal-title":"Cancer Invest"},{"key":"10.1006\/gyno.2000.5793_RF20","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/cncr.2820710422","article-title":"Second-line chemotherapy for recurrent carcinoma of the ovary","volume":"71","author":"Thigpen","year":"1993","journal-title":"Cancer"},{"key":"10.1006\/gyno.2000.5793_RF21","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.1987.5.10.1607","article-title":"Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy","volume":"5","author":"Howell","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5793_RF22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/gyno.1996.0163","article-title":"Intraperitoneal mitoxantrone or floxuridine: Effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy\u2014A randomized phase II study by the Southwest Oncology Group","volume":"61","author":"Muggia","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5793_RF23","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","article-title":"Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group study","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5793_RF24","first-page":"87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: The role of topotecan in second-line chemotherapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist"},{"key":"10.1006\/gyno.2000.5793_RF25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/gyno.1998.4997","article-title":"\u201cRecurrence within 6 months of platinum therapy\u201d: An adequate definition of \u201cplatinum-refractory\u201d ovarian cancer","volume":"69","author":"Markman","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5793_RF26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1200\/JCO.1989.7.9.1327","article-title":"Intraperitoneal cisplatin and etoposide in the treatment of refractory\/recurrent ovarian carcinoma","volume":"7","author":"Reichman","year":"1989","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825800957937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825800957937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T04:41:56Z","timestamp":1576471316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825800957937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,6]]}},"alternative-id":["S0090825800957937"],"URL":"https:\/\/doi.org\/10.1006\/gyno.2000.5793","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2000,6]]}}}